Primary liver cancer

Q2 marked continued progress for Medivir in advanced liver cancer

Q2 saw continued progress for Medivir in advanced liver cancer

Medivir presented greatly improved results for patients with advanced liver cancer in the ongoing phase Ib/IIa study with fostrox in combination...
Medivir

Medivir presents promising results in difficult-to-treat patient population

Medivir today presents new clinical data from its...

Intervju
Medivir optimizes study design after meeting with FDA

Medivir optimizes study design after meeting with FDA

Medivir has had another meeting with the FDA...

Intervju

Medivir continues to accelerate development with fostrox

Medivir's recently published annual report for 2023 focuses primarily on...

Intervju
Pia Baumann, CMO Medivir

Medivir's CMO: "Our new clinical data is very encouraging"

Medivir presents the first clinical results with fostrox...

Intervju
Medivir announces improved durable clinical benefit with fostrox

Medivir sees lasting clinical benefit with fostrox

Medivir, whose ongoing rights issue ends today, the 21st...
Medivir clears key hurdles ahead of phase IIb

Medivir checks off two steps ahead of Phase IIb

Medivir, which is currently in the process of issuing shares, has made progress in a short time...
Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"

Medivir's CEO comments on the ongoing rights issue

Medivir is currently conducting a rights issue of up...

Intervju
Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"

Medivir's CEO comments on updated clinical data

Medivir continues to make progress with the drug candidate fostrox...

Intervju